Amphastar Pharmaceuticals Inc. (AMPH)
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors.
Amphastar Pharmaceuticals: Profitable Pharma With Strong Growth
Amphastar Pharmaceuticals is a small-cap pharmaceutical company focused on developing and selling injectable, inhalation, and intranasal products. The company reported a 29% increase in net revenues in 2023, driven by sales growth in glucagon, Primatene MIST, epinephrine, and lidocaine. The recent acquisition of BAQSIMI and approval of Rextovy will further expand Amphastar's product portfolio.
